Karyopharm Therapeutics Inc.
KPTI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $82 | $99 | $278 | $483 |
| - Cash | $62 | $52 | $135 | $190 |
| + Debt | $195 | $177 | $179 | $181 |
| Enterprise Value | $214 | $224 | $322 | $473 |
| Revenue | $145 | $146 | $157 | $210 |
| % Growth | -0.5% | -7% | -25.1% | – |
| Gross Profit | $139 | $141 | $152 | $206 |
| % Margin | 95.9% | 96.6% | 96.7% | 98.4% |
| EBITDA | -$39 | -$118 | -$139 | -$97 |
| % Margin | -26.6% | -81.1% | -88.7% | -46.2% |
| Net Income | -$76 | -$143 | -$165 | -$124 |
| % Margin | -52.6% | -98% | -105.2% | -59.1% |
| EPS Diluted | -9.41 | -18.79 | -30.28 | -24.75 |
| % Growth | 49.9% | 37.9% | -22.3% | – |
| Operating Cash Flow | -$127 | -$93 | -$150 | -$107 |
| Capital Expenditures | -$0 | $0 | -$0 | -$6 |
| Free Cash Flow | -$128 | -$93 | -$150 | -$113 |